So far emerging immunotherapies of immune checkpoint blockade for HCC, like programmed death-1 (PD-1) and cytotoxic T lymphocyte associated antigen 4 (CTLA-4), are still in the start-up stage compared to other tumors. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.